Alternatively, Huffman et al. demonstrate that CCL5 is produced by intra-tumoral myeloid cells in KPC tumors in response to CD40 agonism and is crucial for the influx of CD4+ T cells and anti-tumor effects seen with immunotherapy [34]. The gene discussed is CCL5; the disease is neoplasm.